Physician profile
Lauren E Redd
NPI 1194242735
$6,144.66
in general payments reported to CMS, 2019-2025
27 companies · $2,486 in 2025
The $2,486 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $807 · 2023: $1,011 · 2024: $1,841 · 2025: $2,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,882 · Education: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,881.86 |
| Education | $455.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,011.17 | 2022-2025 | |
| Janssen Biotech, INC. | $730.44 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $613.28 | 2023-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $608.29 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $518.83 | 2022-2025 | |
| Galderma Laboratories, L.P. | $321.58 | 2024-2025 | Aklief, Nemluvio |
| Lilly USA, LLC | $287.04 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $273.00 | 2022-2025 | Winlevi, Absorica Ld |
| Janssen Scientific Affairs, LLC | $232.74 | 2022 | |
| Organon LLC | $206.63 | 2025 | Vtama |
| Dermavant Sciences, INC. | $200.62 | 2023-2024 | Vtama |
| Pfizer INC. | $183.93 | 2022-2025 | |
| Incyte Corporation | $152.93 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $130.02 | 2022-2025 | |
| Ucb, INC. | $119.13 | 2024-2025 | Bimzelx |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $118.07 | 2022-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $106.25 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $82.57 | 2025 | Zoryve |
| Boston Scientific Corporation | $53.78 | 2025 | Varithena Administration Pack |
| Cipher Pharmaceuticals US LLC | $41.02 | 2025 | Spinosad, Natroba |
| Lnhc, INC | $36.72 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.64 | 2024 | Spevigo |
| Amgen INC. | $21.93 | 2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.08 | 2025 | Jublia, Cabtreo |
| Journey Medical Corporation | $17.24 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.97 | 2022 | |
| Almirall LLC | $13.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Redd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.